News | July 03, 2012

FSS Announces CE Mark for its FlexStent Iliac Self Expanding Stent System

July 3, 2012 — Flexible Stenting Solutions Inc., a leading developer of next generation peripheral arterial, venous, neurovascular and biliary stents, announced that it has extended its CE mark authorized family of peripheral vascular stents to include the FlexStent iliac self expanding stent system.

The FlexStent iliac self expanding stent system is indicated for the treatment of symptomatic atherosclerotic disease of the common and/or external iliac arteries. With this product line extension, the FlexStent family of peripheral vascular stent systems now includes stent diameters of 5, 6, 7, 8, 9 and 10 mm, and offers the physician additional options in the treatment of patients with peripheral artery disease (PAD) of the iliac, superficial femoral and popliteal arteries.

The addition of the FlexStent iliac self expanding stent system to the FSS CE mark authorized family of peripheral vascular stents enhances marketing opportunities for FSS products in the European medical device space. Market launch of the FlexStent iliac self expanding stent system in Europe is expected in Q3 2012.

As with the FlexStent femoropopliteal self expanding stent system, the FlexStent iliac self expanding stent system is an innovative, nearly fully connected, flexible, strong and durable nitinol stent delivered from a straightforward stent delivery system. In addition to simplicity and ease of use, the 6 French / .035" over the wire delivery system provides the physician with a means for very accurate stent deployment.

For more information: www.flexiblestent.com


Related Content

News | Peripheral Artery Disease (PAD)

June 13, 2022 — Royal Philips announced the latest results from the Tack Optimized Balloon Angioplasty (TOBA) II below ...

Home June 13, 2022
Home
News | Peripheral Artery Disease (PAD)

May 20, 2022 — New long-term data from the Safety Assessment of Femoropopliteal Endovascular Treatment With PAclitaxel ...

Home May 20, 2022
Home
News | Peripheral Artery Disease (PAD)

May 19, 2022 — One year outcomes from the Disrupt PAD III Trial comparing intravascular lithotripsy (IVL) with a drug ...

Home May 19, 2022
Home
News | Peripheral Artery Disease (PAD)

March 22, 2022 – With 60 years of experience, The Cardiovascular Care Group is nationally recognized for vascular and ...

Home March 22, 2022
Home
News | Peripheral Artery Disease (PAD)
February 21, 2022 – A research group the Department of Cardiovascular Medicine, Osaka City University Graduate School of ...
Home February 21, 2022
Home
News | Peripheral Artery Disease (PAD)
February 15, 2022 – Alkem Laboratories Limited (Alkem), an Indian multinational pharmaceutical company, has signed a ...
Home February 15, 2022
Home
News | Peripheral Artery Disease (PAD)

January 17, 2022 – The Vascular Care Group (TVCG) announced Stephen J. Hoenig M.D., successfully completed a ...

Home January 17, 2022
Home
News | Peripheral Artery Disease (PAD)

October 20, 2021 — Boston Scientific Corporation announced positive data for the Eluvia Drug-Eluting Vascular Stent ...

Home October 20, 2021
Home
News | Peripheral Artery Disease (PAD)

June 7, 2021 — A couple years ago a study showed a mortality safety signal in patients who underwent peripheral artery ...

Home June 07, 2021
Home
News | Peripheral Artery Disease (PAD)

May 17, 2021 — The anticoagulant rivaroxaban (Xarelto), in addition to low-dose aspirin, significantly reduced the ...

Home May 17, 2021
Home
Subscribe Now